Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study.

ABSTRACT:

Background

The study aimed to evaluate real-world effectiveness and toxicity data of trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in pretreated patients with metastatic breast cancer (mBC).

Patients and methods

A retrospective multicenter review of medical records of patients with mBC treated with T-DXd and/or SG at 24 Departments of Oncology, affiliated with the Hellenic Cooperative Oncology Group (HeCOG) was carried out. Patients with triple-negative BC (TNBC), HER2-positive, and/or hormone receptor (HR)-positive mBC who received at least one cycle of T-DXd and/or SG in any line of treatment were included. The primary endpoint was the toxicity rate of each drug.

Results

From January 2020 to April 2024, 312 patients received treatment; 226 (72.4%) re

SUBMITTER: Fountzilas E 

PROVIDER: S-EPMC12836521 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature